Gyre Therapeutics Seeks Compliance Amid Board Reshuffle
Company Announcements

Gyre Therapeutics Seeks Compliance Amid Board Reshuffle

Gyre Therapeutics (GYRE) has shared an announcement.

Gyre Therapeutics, Inc. has reported a vacancy on its Audit Committee following the resignation of Nassim Usman from the company’s Board and Audit Committee, effective June 30, 2024. The company is currently not in compliance with Nasdaq’s audit committee requirements but has been granted a cure period to address this issue. Gyre Therapeutics is actively seeking a new independent director to fill the vacancy and meet Nasdaq’s standards before the cure period expires, with the goal of reestablishing compliance and maintaining its Nasdaq listing. Dr. Usman’s departure was not due to any disputes regarding the company’s operations or practices.

For detailed information about GYRE stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGyre Therapeutics Reports Q3 2024 Financial Results and Strategic Updates
TheFlyGyre Therapeutics files $150M mixed securities shelf
TheFlyGyre: Last patient completes trial evaluating F351 for CHB-liver fibrosis
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App